Similar Search Results

Integrated product policy and environmental product innovations : an empirical analysis

Rehfeld, Katharina-Maria (contributor); … - 2004 - [Elektronische Ressource]

Persistent link: https://www.econbiz.de/10002368224

Do university based regions really attract outside entrepreneurs : the case of the German biotechnology industry

Engel, Dirk (contributor); Heneric, Oliver (contributor) - 2005

The paper tests empirically the role of knowledge stocks to explain the regional distribution of Germany …’s biotechnology founders. We present an unique approach to highlight the role of knowledge spillovers as we differentiate according …

Persistent link: https://www.econbiz.de/10003114223

Stimuliert der BioRegio-Wettbewerb die Bildung von Biotechnologieclustern in Deutschland? : Ergebnisse einer ökonomischen Analyse

Engelhardt, Dirk (contributor); Heneric, Oliver (contributor) - 2005

Regions with biotechnology-specific knowledge seem to have best chances to attract potential entrepreneurs to establish … a biotechnology-firm. Furthermore, regional oriented technology policy is supposed to stimulate the creation process of … biotechnology clusters, too. The BioRegio contest (BRC) is the most prominent example for this kind of policy support. The analysis …

Persistent link: https://www.econbiz.de/10003051041

Against the one-way-street : analyzing knowledge transfer from industry to science

Fier, Heide; Pyka, Andreas - 2010

industry and from industry to science in the biotechnology sector. In order to model these knowledge flows a citation analysis … ; biotechnology industry …

Persistent link: https://www.econbiz.de/10003989029

Public RD policy : the right turns of the wrong screw? : The case of the German biotechnology industry

Fier, Andreas (contributor); Heneric, Oliver (contributor) - 2005

The German biotechnology industry missed the accession of this key technology in the 1980s. Policy makers make … biotech industry in Germany. We assume that R&D policy was driven blind by the idea to catch up with world’s biotech … leaders and analyse if Germany’s R&D policy lost its origins. We do examine, if Germany sacrifice economic funding …

Persistent link: https://www.econbiz.de/10003178532

Biomedical academic entrepreneurship through the SBIR program

Toole, Andrew A. (contributor); Czarnitzki, Dirk (contributor) - 2005

This paper considers the U.S. Small Business Innovation Research (SBIR) program as a policy fostering academic entrepreneurship. We highlight two main characteristics of the program that make it attractive as an entrepreneurship policy: early-stage financing and scientist involvement in...

Persistent link: https://www.econbiz.de/10003025585

Ex-post assessment of merger effects : the case of Pfizer and Pharmacia (2003)

Leheyda, Nina; Beschorner, Patrick Frank Ernst; … - 2011

The paper studies the effects of the Pfizer and Pharmacia (2003) merger on competition in the Swiss pharmaceutical market and compares the assessment of the Swiss Competition Commission (COMCO) with the post-merger market developments. We find that the merger has had a miniscule impact on the...

Persistent link: https://www.econbiz.de/10009011228

The impact of public basic research on industrial innovation : evidence from the pharmaceutical industry

Toole, Andrew A. - 2011 - This version: March 2011

While most economists believe that public scientific research fuels industry innovation and economic growth, systematic evidence supporting this relationship is surprisingly limited. In a recent study, Acemoglu and Linn (2004) identified market size as a significant driver of drug innovation in...

Persistent link: https://www.econbiz.de/10009374417

Which form of venture capital is most supportive of innovation?

Bertoni, Fabio; Tykvová, Tereza - 2012

Although there seems to be consensus in the literature that venture capital investors increase the innovation output of their portfolio companies, there is little evidence about how investor type (governmental vs. private) and transaction structure (syndicated vs. non-syndicated) moderate this...

Persistent link: https://www.econbiz.de/10009510109

Regulation of pharmaceutical prices : evidence from a reference price reform in Denmark

Kaiser, Ulrich; Méndez, Susan J.; Rønde, Thomas - 2010

On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate...

Persistent link: https://www.econbiz.de/10008660633